Events | 2018.01.03
MMJ International Holdings Files US Patent Prior To FDA Study For Cannabinoid Treatment Medicine
MMJ BioScience’s expected FDA approval for its new medicine would have a major impact on the state to state emerging cannabis industry, which is not federally legal. MMJ BioScience would be able to sell its medicine in pharmacies, once prescribed by physicians, while the FDA continues to issue cease and desist letters to firms marketing unapproved cannabinoid products, preventing non-pharmaceutical companies from exporting their products across state lines.
(PRWeb January 03, 2018)
Read the full story at http://www.prweb.com/releases/2018/01/prweb15051126.htm
For more information, please visit
http://www.prweb.com/releases/2018/01/prweb15051126.htm
